YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
(RTTNews) - GT Biopharma Inc. (GTBP), a clinical-stage immuno-oncology company, on Friday announced first quarter results and provided updates on its developing pipeline. The company is advancing cancer therapeutics through its proprietary…
Issued on behalf of GT Biopharma, Inc. After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, and other historically immunotherapy-resistant solid tumors are suddenly among the busiest batt…
Phase 1trial evaluating GTB-3650TriKE® continues to actively enroll, with the next update anticipated in Q3 2026 following completion of enrollment in dose Cohort 5 Phase 1 basket trial evaluating GTB-5550 TriKE® in multiple solid tumor ty…
VANCOUVER, British Columbia, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Equity InsiderMarket Intelligence Brief – The 2026 economy has hit the wall of physical limits. After a decade of rewarding "potential," the market has pivoted to demanding pro…
(RTTNews) - GT Biopharma, Inc. (GTBP) on Thursday said it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for GTB-5550 TriKE, designed to target B7-H3 expressing solid tumor cancers. A P…
VANCOUVER, British Columbia, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Equity InsiderNews Commentary – The U.S. oncology market is projected to surge from $81 billion in 2025 to $212 billion by 2034[1], driven by a fundamental shift in how physici…
Phase 1trial evaluating GTB-3650TriKE® for relapsed or refractory (r/r) CD33expressing hematologic malignancies continues to actively enroll with the next update anticipated in Q1 2026 GTB-5550TriKE®INDsubmissionfor B7H3-expressingsolidtum…
* GT Biopharma (NASDAQ:GTBP [https://seekingalpha.com/symbol/GTBP]) filed to sell 14.59 million common stock. * This prospectus is not an offer to sell these securities. * The company will not receive any proceeds from the sale of common s…
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER CHANGE COMMENT GTBP [https://www.chartmill.com/stock/quote/GTBP/profile] 29.79…
GTB-3650 TriKE® Phase 1 trial has successfully completed Cohort 1 and Cohort 2 dosing, treating a total of four patients; following Cohort 2’s formal safety review, it has advanced into Cohort 3 and initiated dosing of the fifth patient in…
The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues observed The company plans on releasing initial…
SAN FRANCISCO, CALIFORNIA, June 13, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE…
* GT Biopharma (NASDAQ:GTBP [https://seekingalpha.com/symbol/GTBP]) is registering 120.55M shares of common stock for resale by selling stockholders. * Shares include those issuable from preferred stock conversions, warrant exercises, gree…
Following the formal safety review of Cohort 1, no safety or tolerability issues were observed, allowing the company to move forward with Cohort 2. The company plans on releasing more detailed results from Phase 1 later in 2025 following c…
SAN FRANCISCO, CALIFORNIA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE…
BRISBANE, CALIFORNIA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell e…
IND submission for GTB-3650, 2nd generation nanobody TriKE® for treatment of CD33+ leukemia, expected in Q4 2023Phase 1 clinical trial initiation evaluating GTB-3650 for treatment of CD33+ leukemia anticipated in 2024Cash of approximately…
Cash of approximately $18.0 million as of June 30, 2023,provides ample runway to fund operations into Q32024; anticipated to be sufficient to achieve IND clearance for GTB-3650 and initiate clinical trial activities on GTB-3650. BRISBANE,…
Believe Urgent Change is Needed at Research Solutions to Address Underperformance, Poor Operational Execution, and Lack of Accountability Highlight that Since Roy Olivier Became Chief Executive Officer, Research Solutions’ Share Price Has…
GT Biopharma, Inc. BRISBANE, CALIFORNIA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural…
BRISBANE, CALIFORNIA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell e…
GT Biopharma, Inc. Cash of approximately $19.9 million as of March31, 2023,provides ample runway to fund operations into Q2 2024; anticipated to be sufficient to achieve IND clearance for GTB-3650 and GTB-5550, and initiate clinical trial…
Cash of approximately $19.9 million as of March31, 2023,provides ample runway to fund operations into Q2 2024; anticipated to be sufficient to achieve IND clearance for GTB-3650 and GTB-5550, and initiate clinical trial activities on GTB-3…
GT Biopharma, Inc. BRISBANE, CALIFORNIA, May 04, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s prop…
BRISBANE, CALIFORNIA, May 04, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural kil…
Proforma cash of approximately $23.0 million includes $16.5million in cash as of December 31, 2022, plus $6.5 million in gross proceeds received from a registered direct offering priced at a premium to market on January 4, 2023.Cash on han…
GT Biopharma, Inc. Proforma cash of approximately $23.0 million includes $16.5million in cash as of December 31, 2022, plus $6.5 million in gross proceeds received from a registered direct offering priced at a premium to market on January…
BRISBANE, CALIFORNIA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell e…
BRISBANE, CALIFORNIA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell e…
GT Biopharma, Inc. BRISBANE, CALIFORNIA, Feb. 02, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Comp…
BRISBANE, CALIFORNIA, Feb. 02, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary n…
GT Biopharma, Inc. BRISBANE, CALIFORNIA, Dec. 30, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Comp…
BRISBANE, CALIFORNIA, Dec. 30, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary n…
BRISBANE, CALIFORNIA, Dec. 14, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary n…
GT Biopharma, Inc. BRISBANE, CALIFORNIA, Dec. 14, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Comp…
Presentation shows the therapeutic potential of combining iPSC-derived CAR NK cellsand NK cell engagers to overcome the clinical heterogeneity of AML BRISBANE, CALIFORNIA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP)…